schliessen

Filtern

 

Bibliotheken

Hepatitis B virus infection

Summary Hepatitis B virus infection is a major public health problem worldwide; roughly 30% of the world's population show serological evidence of current or past infection. Hepatitis B virus is a partly double-stranded DNA virus with several serological markers: HBsAg and anti-HBs, HBeAg and anti-H... Full description

Journal Title: The Lancet (British edition) 2014, Vol.384 (9959), p.2053-2063
Main Author: Trépo, Christian, Prof
Other Authors: Chan, Henry L Y, Prof , Lok, Anna, Prof
Format: Electronic Article Electronic Article
Language: English
Subjects:
DNA
Quelle: Alma/SFX Local Collection
Publisher: Kidlington: Elsevier Ltd
ID: ISSN: 0140-6736
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_1661621212
title: Hepatitis B virus infection
format: Article
creator:
  • Trépo, Christian, Prof
  • Chan, Henry L Y, Prof
  • Lok, Anna, Prof
subjects:
  • Abridged Index Medicus
  • Biological and medical sciences
  • Blood & organ donations
  • Deoxyribonucleic acid
  • DNA
  • General aspects
  • Hepatitis
  • Hepatitis B - diagnosis
  • Hepatitis B - epidemiology
  • Hepatitis B - prevention & control
  • Hepatitis B - therapy
  • Hepatitis B virus
  • Human viral diseases
  • Humans
  • Infectious diseases
  • Interferons - therapeutic use
  • Internal Medicine
  • Liver cancer
  • Medical sciences
  • Mortality
  • Nosocomial infections
  • Vaccines
  • Viral diseases
  • Viral hepatitis
  • Viral infections
ispartof: The Lancet (British edition), 2014, Vol.384 (9959), p.2053-2063
description: Summary Hepatitis B virus infection is a major public health problem worldwide; roughly 30% of the world's population show serological evidence of current or past infection. Hepatitis B virus is a partly double-stranded DNA virus with several serological markers: HBsAg and anti-HBs, HBeAg and anti-HBe, and anti-HBc IgM and IgG. It is transmitted through contact with infected blood and semen. A safe and effective vaccine has been available since 1981, and, although variable, the implementation of universal vaccination in infants has resulted in a sharp decline in prevalence. Hepatitis B virus is not cytopathic; both liver damage and viral control—and therefore clinical outcome—depend on the complex interplay between virus replication and host immune response. Overall, as much as 40% of men and 15% of women with perinatally acquired hepatitis B virus infection will die of liver cirrhosis or hepatocellular carcinoma. In addition to decreasing hepatic inflammation, long-term antiviral treatment can reverse cirrhosis and reduce hepatocellular carcinoma. Development of new therapies that can improve HBsAg clearance and virological cure is warranted.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0140-6736
fulltext: fulltext
issn:
  • 0140-6736
  • 1474-547X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.8583257
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_1661621212
sourceformatXML
sourcesystemPC
galeidA394588115
sourcerecordidA394588115
originalsourceidFETCH-LOGICAL-c690t-482fb18e92f21350c650cb704b44c2c70fd362287148fc5e0cab48e50fd1b1f73
addsrcrecordideNqNkuFr1DAYxoso7jb9C0Q5kMEEO_OmSZoiKHOoEwZ-UMFvIU3fnpm99szbDvbfm96dd-5weISkEH7Pw_s0T5I8BXYKDNSrLwwES1WeqRMQLxTjnKX6XjIBkYtUivz7_WSyQQ6SQ6IrxphQTD5MDrgopFC5nCRPLnBhe997mr6bXvsw0NS3Nbred-2j5EFtG8LH6-9R8u3D-6_nF-nl54-fzs8uU6cK1qdC87oEjQWvOWSSORV3mTNRCuG4y1ldZYpznYPQtZPInC2FRhnvoYQ6z46Sk5XvInS_BqTezD05bBrbYjeQAaVAcYhrDzTm0pLLbA80EznPGC8i-nwHveqG0MbMIxXjZFzBlprZBk38S10frBtNzVlWCKk1gIzU6T-ouCqce9e1WPt4f0vw8i9BOZBvkeJBfvajp5kdiG7jcoW70BEFrM0i-LkNNwaYGZthls0w47MbEGbZDKOj7tk641DOsdqo_lQhAsdrwJKzTR1s6zxtuSK2B7SK3OudAZzv7diXGNQ3mzHojjH2U98V4u1KjbGO1x6DIeexdVj5EDtrqs7_1-HNjoNrfOtj4J94g7R9d0PcsJXJ6AFi6aCz3-PnCCw
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1636503261
display
typearticle
titleHepatitis B virus infection
sourceAlma/SFX Local Collection
creatorTrépo, Christian, Prof ; Chan, Henry L Y, Prof ; Lok, Anna, Prof
creatorcontribTrépo, Christian, Prof ; Chan, Henry L Y, Prof ; Lok, Anna, Prof
descriptionSummary Hepatitis B virus infection is a major public health problem worldwide; roughly 30% of the world's population show serological evidence of current or past infection. Hepatitis B virus is a partly double-stranded DNA virus with several serological markers: HBsAg and anti-HBs, HBeAg and anti-HBe, and anti-HBc IgM and IgG. It is transmitted through contact with infected blood and semen. A safe and effective vaccine has been available since 1981, and, although variable, the implementation of universal vaccination in infants has resulted in a sharp decline in prevalence. Hepatitis B virus is not cytopathic; both liver damage and viral control—and therefore clinical outcome—depend on the complex interplay between virus replication and host immune response. Overall, as much as 40% of men and 15% of women with perinatally acquired hepatitis B virus infection will die of liver cirrhosis or hepatocellular carcinoma. In addition to decreasing hepatic inflammation, long-term antiviral treatment can reverse cirrhosis and reduce hepatocellular carcinoma. Development of new therapies that can improve HBsAg clearance and virological cure is warranted.
identifier
0ISSN: 0140-6736
1EISSN: 1474-547X
2DOI: 10.1016/S0140-6736(14)60220-8
3PMID: 24954675
4CODEN: LANCAO
languageeng
publisherKidlington: Elsevier Ltd
subjectAbridged Index Medicus ; Biological and medical sciences ; Blood & organ donations ; Deoxyribonucleic acid ; DNA ; General aspects ; Hepatitis ; Hepatitis B - diagnosis ; Hepatitis B - epidemiology ; Hepatitis B - prevention & control ; Hepatitis B - therapy ; Hepatitis B virus ; Human viral diseases ; Humans ; Infectious diseases ; Interferons - therapeutic use ; Internal Medicine ; Liver cancer ; Medical sciences ; Mortality ; Nosocomial infections ; Vaccines ; Viral diseases ; Viral hepatitis ; Viral infections
ispartofThe Lancet (British edition), 2014, Vol.384 (9959), p.2053-2063
rights
0Elsevier Ltd
12014 Elsevier Ltd
22015 INIST-CNRS
3Copyright © 2014 Elsevier Ltd. All rights reserved.
4COPYRIGHT 2014 Elsevier B.V.
5Copyright Elsevier Limited Dec 6, 2014
lds50peer_reviewed
citedbyFETCH-LOGICAL-c690t-482fb18e92f21350c650cb704b44c2c70fd362287148fc5e0cab48e50fd1b1f73
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=29004186$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24954675$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Trépo, Christian, Prof
1Chan, Henry L Y, Prof
2Lok, Anna, Prof
title
0Hepatitis B virus infection
1The Lancet (British edition)
addtitleLancet
descriptionSummary Hepatitis B virus infection is a major public health problem worldwide; roughly 30% of the world's population show serological evidence of current or past infection. Hepatitis B virus is a partly double-stranded DNA virus with several serological markers: HBsAg and anti-HBs, HBeAg and anti-HBe, and anti-HBc IgM and IgG. It is transmitted through contact with infected blood and semen. A safe and effective vaccine has been available since 1981, and, although variable, the implementation of universal vaccination in infants has resulted in a sharp decline in prevalence. Hepatitis B virus is not cytopathic; both liver damage and viral control—and therefore clinical outcome—depend on the complex interplay between virus replication and host immune response. Overall, as much as 40% of men and 15% of women with perinatally acquired hepatitis B virus infection will die of liver cirrhosis or hepatocellular carcinoma. In addition to decreasing hepatic inflammation, long-term antiviral treatment can reverse cirrhosis and reduce hepatocellular carcinoma. Development of new therapies that can improve HBsAg clearance and virological cure is warranted.
subject
0Abridged Index Medicus
1Biological and medical sciences
2Blood & organ donations
3Deoxyribonucleic acid
4DNA
5General aspects
6Hepatitis
7Hepatitis B - diagnosis
8Hepatitis B - epidemiology
9Hepatitis B - prevention & control
10Hepatitis B - therapy
11Hepatitis B virus
12Human viral diseases
13Humans
14Infectious diseases
15Interferons - therapeutic use
16Internal Medicine
17Liver cancer
18Medical sciences
19Mortality
20Nosocomial infections
21Vaccines
22Viral diseases
23Viral hepatitis
24Viral infections
issn
00140-6736
11474-547X
fulltexttrue
rsrctypearticle
creationdate2014
recordtypearticle
recordideNqNkuFr1DAYxoso7jb9C0Q5kMEEO_OmSZoiKHOoEwZ-UMFvIU3fnpm99szbDvbfm96dd-5weISkEH7Pw_s0T5I8BXYKDNSrLwwES1WeqRMQLxTjnKX6XjIBkYtUivz7_WSyQQ6SQ6IrxphQTD5MDrgopFC5nCRPLnBhe997mr6bXvsw0NS3Nbred-2j5EFtG8LH6-9R8u3D-6_nF-nl54-fzs8uU6cK1qdC87oEjQWvOWSSORV3mTNRCuG4y1ldZYpznYPQtZPInC2FRhnvoYQ6z46Sk5XvInS_BqTezD05bBrbYjeQAaVAcYhrDzTm0pLLbA80EznPGC8i-nwHveqG0MbMIxXjZFzBlprZBk38S10frBtNzVlWCKk1gIzU6T-ouCqce9e1WPt4f0vw8i9BOZBvkeJBfvajp5kdiG7jcoW70BEFrM0i-LkNNwaYGZthls0w47MbEGbZDKOj7tk641DOsdqo_lQhAsdrwJKzTR1s6zxtuSK2B7SK3OudAZzv7diXGNQ3mzHojjH2U98V4u1KjbGO1x6DIeexdVj5EDtrqs7_1-HNjoNrfOtj4J94g7R9d0PcsJXJ6AFi6aCz3-PnCCw
startdate2014
enddate2014
creator
0Trépo, Christian, Prof
1Chan, Henry L Y, Prof
2Lok, Anna, Prof
general
0Elsevier Ltd
1Elsevier
2Elsevier B.V
3Elsevier Limited
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
9BSHEE
100TT
110TZ
120U~
133V.
147QL
157QP
167RV
177TK
187U7
197U9
207X7
217XB
2288A
2388C
2488E
2588G
2688I
278AF
288AO
298C1
308C2
318FE
328FH
338FI
348FJ
358FK
368G5
37ABUWG
38AN0
39ASE
40AZQEC
41BBNVY
42BEC
43BENPR
44BHPHI
45C1K
46DWQXO
47FPQ
48FYUFA
49GHDGH
50GNUQQ
51GUQSH
52H94
53HCIFZ
54K6X
55K9-
56K9.
57KB0
58KB~
59LK8
60M0R
61M0S
62M0T
63M1P
64M2M
65M2O
66M2P
67M7N
68M7P
69MBDVC
70NAPCQ
71PQEST
72PQQKQ
73PQUKI
74Q9U
75S0X
767X8
777T2
787U2
sort
creationdate2014
titleHepatitis B virus infection
authorTrépo, Christian, Prof ; Chan, Henry L Y, Prof ; Lok, Anna, Prof
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c690t-482fb18e92f21350c650cb704b44c2c70fd362287148fc5e0cab48e50fd1b1f73
rsrctypearticles
prefilterarticles
languageeng
creationdate2014
topic
0Abridged Index Medicus
1Biological and medical sciences
2Blood & organ donations
3Deoxyribonucleic acid
4DNA
5General aspects
6Hepatitis
7Hepatitis B - diagnosis
8Hepatitis B - epidemiology
9Hepatitis B - prevention & control
10Hepatitis B - therapy
11Hepatitis B virus
12Human viral diseases
13Humans
14Infectious diseases
15Interferons - therapeutic use
16Internal Medicine
17Liver cancer
18Medical sciences
19Mortality
20Nosocomial infections
21Vaccines
22Viral diseases
23Viral hepatitis
24Viral infections
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Trépo, Christian, Prof
1Chan, Henry L Y, Prof
2Lok, Anna, Prof
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8Academic OneFile (A&I only)
9News PRO
10Pharma and Biotech Premium PRO
11Global News & ABI/Inform Professional
12ProQuest Central (Corporate)
13Bacteriology Abstracts (Microbiology B)
14Calcium & Calcified Tissue Abstracts
15Nursing & Allied Health Database
16Neurosciences Abstracts
17Toxicology Abstracts
18Virology and AIDS Abstracts
19Health & Medical Collection
20ProQuest Central (purchase pre-March 2016)
21Biology Database (Alumni Edition)
22Healthcare Administration Database (Alumni)
23Medical Database (Alumni Edition)
24Psychology Database (Alumni)
25Science Database (Alumni Edition)
26STEM Database
27ProQuest Pharma Collection
28Public Health Database
29Lancet Titles
30ProQuest SciTech Collection
31ProQuest Natural Science Collection
32Hospital Premium Collection
33Hospital Premium Collection (Alumni Edition)
34ProQuest Central (Alumni) (purchase pre-March 2016)
35Research Library (Alumni Edition)
36ProQuest Central (Alumni Edition)
37British Nursing Database
38British Nursing Index
39ProQuest Central Essentials
40Biological Science Collection
41eLibrary
42ProQuest Central
43Natural Science Collection
44Environmental Sciences and Pollution Management
45ProQuest Central Korea
46British Nursing Index (BNI) (1985 to Present)
47Health Research Premium Collection
48Health Research Premium Collection (Alumni)
49ProQuest Central Student
50Research Library Prep
51AIDS and Cancer Research Abstracts
52SciTech Premium Collection
53British Nursing Index
54Consumer Health Database (Alumni Edition)
55ProQuest Health & Medical Complete (Alumni)
56Nursing & Allied Health Database (Alumni Edition)
57ProQuest Newsstand Professional
58ProQuest Biological Science Collection
59Consumer Health Database
60Health & Medical Collection (Alumni Edition)
61Healthcare Administration Database
62Medical Database
63Psychology Database
64Research Library
65Science Database
66Algology Mycology and Protozoology Abstracts (Microbiology C)
67Biological Science Database
68Research Library (Corporate)
69Nursing & Allied Health Premium
70ProQuest One Academic Eastern Edition
71ProQuest One Academic
72ProQuest One Academic UKI Edition
73ProQuest Central Basic
74SIRS Editorial
75MEDLINE - Academic
76Health and Safety Science Abstracts (Full archive)
77Safety Science and Risk
jtitleThe Lancet (British edition)
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Trépo, Christian, Prof
1Chan, Henry L Y, Prof
2Lok, Anna, Prof
formatjournal
genrearticle
ristypeJOUR
atitleHepatitis B virus infection
jtitleThe Lancet (British edition)
addtitleLancet
date2014
risdate2014
volume384
issue9959
spage2053
epage2063
pages2053-2063
issn0140-6736
eissn1474-547X
codenLANCAO
abstractSummary Hepatitis B virus infection is a major public health problem worldwide; roughly 30% of the world's population show serological evidence of current or past infection. Hepatitis B virus is a partly double-stranded DNA virus with several serological markers: HBsAg and anti-HBs, HBeAg and anti-HBe, and anti-HBc IgM and IgG. It is transmitted through contact with infected blood and semen. A safe and effective vaccine has been available since 1981, and, although variable, the implementation of universal vaccination in infants has resulted in a sharp decline in prevalence. Hepatitis B virus is not cytopathic; both liver damage and viral control—and therefore clinical outcome—depend on the complex interplay between virus replication and host immune response. Overall, as much as 40% of men and 15% of women with perinatally acquired hepatitis B virus infection will die of liver cirrhosis or hepatocellular carcinoma. In addition to decreasing hepatic inflammation, long-term antiviral treatment can reverse cirrhosis and reduce hepatocellular carcinoma. Development of new therapies that can improve HBsAg clearance and virological cure is warranted.
copKidlington
pubElsevier Ltd
pmid24954675
doi10.1016/S0140-6736(14)60220-8